EW Q3 2022 Earnings — Edwards Lifesciences Corporation Revenue & Financial Results | Market Cap Arena

EWEdwards Lifesciences Corporation

$50B

Q3 2022 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$1.3B+0.7% YoY

Gross Profit

$1.0B78.7% margin

Operating Income

$427M32.4% margin

Net Income

$344M26.0% margin

EPS (Diluted)

$0.55

QoQ Revenue Growth

-4.0%

Cash Flow

Operating Cash Flow

$310M

Free Cash Flow

$250M

Stock-Based Comp.

$30M

Balance Sheet

Total Assets

$8.6B

Total Liabilities

$2.4B

Stockholders' Equity

$6.2B

Cash & Equivalents

$1.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.3B	$1.3B	+0.7%
Gross Profit	$1.0B	$1.0B	+2.9%
Operating Income	$427M	$407M	+4.9%
Net Income	$344M	$340M	+1.0%

Revenue Segments

Transcatheter Heart Valves

$862M65%

Surgical Heart Valve Therapy

$220M17%

Critical Care

$207M16%

Transcatheter Mitral And Tricuspid Therapies

$30M2%

Geographic Segments

UNITED STATES

$787M60%

Europe

$270M20%

Rest of World

$158M12%

JAPAN

$104M8%